Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute of Human Genetics Munich, |
RCV003335820 | SCV004045916 | pathogenic | X-linked Alport syndrome | 2023-06-21 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004978831 | SCV005564174 | likely pathogenic | Inborn genetic diseases | 2024-10-18 | criteria provided, single submitter | clinical testing | The c.546+1G>A intronic variant results from a G to A substitution one nucleotide after coding exon 9 of the COL4A5 gene. Alterations that disrupt the canonical splice site are expected to result in aberrant splicing. The resulting transcript is predicted to be in-frame and is not expected to trigger nonsense-mediated mRNAdecay; however, direct evidence is unavailable. The exact functional effect of the altered amino acid sequence is unknown; however, the impacted region is critical for protein function (Ambry internal data). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This variant was reported in individuals with features consistent with X-linked Alport syndrome (Knebelmann,1996). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Based on the available evidence, this alteration is classified as likely pathogenic. |